A meta-analysis of flupentixol and melitracen tablets in the treatment of chronic obstructive pulmonary disease with anxiety and/or depression_West China Medical Journal

Authors：

ZHANG Xia ¹ ,  LIU Zhongyang ² , ZHANG Ling ¹ , GAO Junfeng ²

1. Postgraduate Training Base of the People’s Liberation Army Joint Service Support Force No.967 Hospital, Jinzhou Medical University, Dalian, Liaoning 116021, P. R. China;
2. Department of Respiratory Medicine, the People’s Liberation Army Joint Service Support Force No.967 Hospital Dalian, Liaoning 116021, P. R. China;

Corresponding?author：

LIU Zhongyang, Email: 2030622263@qq.com

Keywords：

Chronic obstructive pulmonary disease; Flupentixol and melitracen tablets; Anxiety; Depression; Meta-analysis

DOI：

10.7507/1002-0179.201910052

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the clinical efficacy of flupentixol and melitracen tablets on the treatment of chronic obstructive pulmonary disease (COPD) with anxiety and/or depression.Methods Randomized controlled trials of flupentixol and melitracen tablets in the treatment of COPD with anxiety and/or depression were retrieved from PubMed, Sciencedirect Database, China National Knowledge Infrastructure, Wanfang Database, and CQVIP Journal Database, with retrieval time from January 2010 to December 2019. Two researchers screened literature and extracted data independently, and meta-analyzed the results using RevMan 5.3 software.Results A total of 9 articles with 1 123 patients were included. There were 567 patients in the trial group receiving flupentixol and melitracen tablets plus symptomatic support therapy and 556 patients in the control group receiving simple symptomatic treatment. After treatment, the Hamilton Anxiety Scale score [mean difference (MD)=?5.10, 95% confidence interval (CI) (?7.67, ?2.54), P<0.000 1] and Hamilton Depression Scale score [MD=?3.94, 95%CI (?6.64, ?1.23), P=0.004] in the trial group were lower than those in the control group, while the forced expiratory volume in one second as percentage of predicted volume [MD=4.89%, 95%CI (0.59%, 9.19%), P=0.03] and COPD Assessment Test score [MD=?3.21, 95%CI (?3.76, ?2.66), P<0.000 01] in the trial group were better than those in the control group.Conclusion Flupentixol and melitracen tablets plus symptomatic support therapy has a better effect than simple symptomatic support treatment on COPD with anxiety and/or depression.

Citation： ZHANG Xia, LIU Zhongyang, ZHANG Ling, GAO Junfeng. A meta-analysis of flupentixol and melitracen tablets in the treatment of chronic obstructive pulmonary disease with anxiety and/or depression. West China Medical Journal, 2020, 35(1): 28-34. doi: 10.7507/1002-0179.201910052 Copy

1.	Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstrutive pulmonary disease. (2018-11-07)[2019-08-01]. https://goldcopd.org/archived-reports/.
2.	Agarwal A, Batra S, Prasad R, et al. A study on the prevalence of depression and the severity of depression in patients of chronic obstructive pulmonary disease in a semi-urban Indian population. Monaldi Arch Chest Dis, 2018, 88(1): 902.
3.	Safa M, Fallah Tafti S, Talischi F, et al. Severity of anxiety disorders in patients with chronic obstructive pulmonary disease. Iran J Psychiatry, 2015, 10(2): 128-132.
4.	丁靜怡. 慢性阻塞性肺疾病合并焦慮抑郁的相關因素分析. 臨床肺科雜志, 2018, 23(4): 690-693.
5.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南. 中華結核和呼吸雜志, 2002, 25(8): 453-460.
6.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2007 年修訂版). 中華結核和呼吸雜志, 2007, 30(1): 8-17.
7.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2013 年修訂版). 中華結核和呼吸雜志, 2013, 36(4): 255-264.
8.	利桂河, 楊培文, 周妙玲, 等. 黛力新聯合思力華治療 COPD 穩定期療效觀察. 中國醫學創新, 2012, 9(16): 129-130.
9.	張國偉, 吳紹嫻, 許荻, 等. 黛力新治療慢性阻塞性肺疾病加重期焦慮抑郁癥. 航空航天醫藥, 2010, 21(7): 1092-1093.
10.	楊曉娟, 張自立, 杜永成. 氟哌噻噸美利曲辛對合并焦慮抑郁的慢性阻塞性肺疾病急性加重期患者治療效果的研究. 中國藥物與臨床, 2014, 14(12): 1682-1684.
11.	王翔, 單洪武, 王東波. 氟哌噻噸美利曲辛輔助方案對 COPD 合并抑郁焦慮患者負面情緒、肺功能及生活質量的影響. 河北醫藥, 2016, 38(4): 540-542.
12.	羅建華, 李隆祥, 張英. 黛力新對絕經期女性穩定期 COPD 患者生活質量的影響. 中國現代醫生, 2012, 50(13): 53-54, 57.
13.	羅麟潔, 范世明, 唐鳳鳴, 等. 氟哌噻噸美利曲辛治療 COPD 合并焦慮/抑郁患者的臨床研究. 云南醫藥, 2016, 37(2): 146-150.
14.	鄒志, 楊嬋娟, 陳開容, 等. 抗焦慮抑郁輔助治療對慢性阻塞性肺疾病患者臨床療效觀察. 臨床肺科雜志, 2016, 21(9): 1627-1631.
15.	郭欣, 李玉超, 劉震宇. 氟哌噻噸美利曲辛片對慢性阻塞性肺疾病合并焦慮抑郁癥狀患者的臨床影響. 中國老年多器官疾病雜志, 2019, 18(7): 523-526.
16.	魏桂蓮, 張澤麗. 黛力新聯合奮乃靜對合并焦慮抑郁的慢性阻塞性肺疾病急性加重患者治療效果研究. 當代醫學, 2018, 24(32): 104-106.
17.	Kyu HH, Abate D, Abate KH, et al. Global, regional, and National disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1859-1922.
18.	Flynn RWV, MacDonald TM, Chalmers JD, et al. The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respir Res, 2018, 19(1): 249.
19.	Martinez Rivera C, Costan Galicia J, Alcázar Navarrete B, et al. Factors associated with depression in COPD: a multicenter study. Lung, 2016, 194(3): 335-343.
20.	Underner M, Cuvelier A, Peiffer G, et al. The influence of anxiety and depression on COPD exacerbations. Rev Mal Respir, 2018, 35(6): 604-625.
21.	Aras YG, Tun? A, Güngen BD, et al. The effects of depression, anxiety and sleep disturbances on cognitive impairment in patients with chronic obstructive pulmonary disease. Cogn Neurodyn, 2017, 11(6): 565-571.
22.	Coventry PA, Bower P, Keyworth CA, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One, 2013, 8(4): e60532.
23.	Smith S, Sonego S, Ketcheson L, et al. A review of the effectiveness of psychological interventions used for anxiety and depression in chronic obstructive pulmonary disease. BMJ Open Resp Res, 2014, 1(1): e000042.
24.	Heslop-Marshall K, Baker C, Carrick-Sen D, et al. Randomised controlled trial of cognitive behavioural therapy in COPD. ERJ Open Res, 2018, 4(4): 00094-2018.
25.	謝欲曉, 盧茜, 段亞景, 等. 肺康復的發展現狀與展望. 華西醫學, 2019, 34(5): 498-502.

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstrutive pulmonary disease. (2018-11-07)[2019-08-01]. https://goldcopd.org/archived-reports/.
2. Agarwal A, Batra S, Prasad R, et al. A study on the prevalence of depression and the severity of depression in patients of chronic obstructive pulmonary disease in a semi-urban Indian population. Monaldi Arch Chest Dis, 2018, 88(1): 902.
3. Safa M, Fallah Tafti S, Talischi F, et al. Severity of anxiety disorders in patients with chronic obstructive pulmonary disease. Iran J Psychiatry, 2015, 10(2): 128-132.
4. 丁靜怡. 慢性阻塞性肺疾病合并焦慮抑郁的相關因素分析. 臨床肺科雜志, 2018, 23(4): 690-693.
5. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南. 中華結核和呼吸雜志, 2002, 25(8): 453-460.
6. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2007 年修訂版). 中華結核和呼吸雜志, 2007, 30(1): 8-17.
7. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2013 年修訂版). 中華結核和呼吸雜志, 2013, 36(4): 255-264.
8. 利桂河, 楊培文, 周妙玲, 等. 黛力新聯合思力華治療 COPD 穩定期療效觀察. 中國醫學創新, 2012, 9(16): 129-130.
9. 張國偉, 吳紹嫻, 許荻, 等. 黛力新治療慢性阻塞性肺疾病加重期焦慮抑郁癥. 航空航天醫藥, 2010, 21(7): 1092-1093.
10. 楊曉娟, 張自立, 杜永成. 氟哌噻噸美利曲辛對合并焦慮抑郁的慢性阻塞性肺疾病急性加重期患者治療效果的研究. 中國藥物與臨床, 2014, 14(12): 1682-1684.
11. 王翔, 單洪武, 王東波. 氟哌噻噸美利曲辛輔助方案對 COPD 合并抑郁焦慮患者負面情緒、肺功能及生活質量的影響. 河北醫藥, 2016, 38(4): 540-542.
12. 羅建華, 李隆祥, 張英. 黛力新對絕經期女性穩定期 COPD 患者生活質量的影響. 中國現代醫生, 2012, 50(13): 53-54, 57.
13. 羅麟潔, 范世明, 唐鳳鳴, 等. 氟哌噻噸美利曲辛治療 COPD 合并焦慮/抑郁患者的臨床研究. 云南醫藥, 2016, 37(2): 146-150.
14. 鄒志, 楊嬋娟, 陳開容, 等. 抗焦慮抑郁輔助治療對慢性阻塞性肺疾病患者臨床療效觀察. 臨床肺科雜志, 2016, 21(9): 1627-1631.
15. 郭欣, 李玉超, 劉震宇. 氟哌噻噸美利曲辛片對慢性阻塞性肺疾病合并焦慮抑郁癥狀患者的臨床影響. 中國老年多器官疾病雜志, 2019, 18(7): 523-526.
16. 魏桂蓮, 張澤麗. 黛力新聯合奮乃靜對合并焦慮抑郁的慢性阻塞性肺疾病急性加重患者治療效果研究. 當代醫學, 2018, 24(32): 104-106.
17. Kyu HH, Abate D, Abate KH, et al. Global, regional, and National disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1859-1922.
18. Flynn RWV, MacDonald TM, Chalmers JD, et al. The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respir Res, 2018, 19(1): 249.
19. Martinez Rivera C, Costan Galicia J, Alcázar Navarrete B, et al. Factors associated with depression in COPD: a multicenter study. Lung, 2016, 194(3): 335-343.
20. Underner M, Cuvelier A, Peiffer G, et al. The influence of anxiety and depression on COPD exacerbations. Rev Mal Respir, 2018, 35(6): 604-625.
21. Aras YG, Tun? A, Güngen BD, et al. The effects of depression, anxiety and sleep disturbances on cognitive impairment in patients with chronic obstructive pulmonary disease. Cogn Neurodyn, 2017, 11(6): 565-571.
22. Coventry PA, Bower P, Keyworth CA, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One, 2013, 8(4): e60532.
23. Smith S, Sonego S, Ketcheson L, et al. A review of the effectiveness of psychological interventions used for anxiety and depression in chronic obstructive pulmonary disease. BMJ Open Resp Res, 2014, 1(1): e000042.
24. Heslop-Marshall K, Baker C, Carrick-Sen D, et al. Randomised controlled trial of cognitive behavioural therapy in COPD. ERJ Open Res, 2018, 4(4): 00094-2018.
25. 謝欲曉, 盧茜, 段亞景, 等. 肺康復的發展現狀與展望. 華西醫學, 2019, 34(5): 498-502.

West China Medical Journal

A meta-analysis of flupentixol and melitracen tablets in the treatment of chronic obstructive pulmonary disease with anxiety and/or depression

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content